Article

Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in Melanoma

2024-06-17

Abstract excerpt

<h4>Summary</h4> PLK1 inhibitors are emerging anti-cancer agents being tested in monotherapy and combination therapies for various cancers. Although PLK1 inhibition in experimental models shows potent antitumor effects, translation to the clinic has been hampered by low antitumor activity and tumor relapse. Here, we report the identification of mitochondrial protein signatures that determine sensitivity to approa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0ba2474d-ce6c-51cd-931f-a6dd19926330
DOI: 10.1101/2024.06.14.599035

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in MelanomaDOI 10.1101/2024.06.14.599035Read

Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors.Semantic proximity Read

Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.Semantic proximity Read

Effects of PD-L1 Inhibitors on Mitochondrial Function in Melanoma A375 Cells: Unveiling a Shielded Drug Resistance MechanismSemantic proximity Read

Treatment resistance to melanoma therapeutics on a single cell level.Semantic proximity Read

Treatment Resistance to Melanoma Therapeutics on a Single Cell LevelSemantic proximity Read

Proteogenomic Characterization Reveals Therapeutic Opportunities Related to Mitochondrial Function in MelanomaSemantic proximity Read

In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 TherapiesSemantic proximity Read

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read

Metabolic rewiring in melanoma drug-resistant cells.Semantic proximity Read

Novel CRISPR-Cas9 BAP1 Knockout Pre-Clinical Tumor Model Recapitulates Human Melanoma Tumorigenesis and Immune EvolutionSemantic proximity Read

Novel CRISPR-Cas9 BAP1 Knockout Pre-Clinical Tumor Model Recapitulates Human Melanoma Tumorigenesis and Immune EvolutionSemantic proximity Read

Emerging targets for combination therapy in melanomasSemantic proximity Read